UBS Group AG Has $2.10 Million Stake in ALT5 Sigma Corporation $AIFC

UBS Group AG lifted its stake in shares of ALT5 Sigma Corporation (NASDAQ:AIFC) by 179.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,904,567 shares of the company’s stock after acquiring an additional 1,222,690 shares during the period. UBS Group AG’s holdings in ALT5 Sigma were worth $2,095,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Profund Advisors LLC acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $28,000. Arete Wealth Advisors LLC acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $28,000. Victory Capital Management Inc. acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $33,000. First Citizens Bank & Trust Co. acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $35,000. Finally, Lantern Wealth Advisors LLC acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

ALT5 Sigma Trading Down 2.0%

ALT5 Sigma stock opened at $0.78 on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03. ALT5 Sigma Corporation has a 12-month low of $0.73 and a 12-month high of $10.95. The firm’s fifty day moving average is $1.02 and its 200 day moving average is $1.43.

ALT5 Sigma (NASDAQ:AIFC) last released its earnings results on Monday, May 18th. The company reported ($2.14) earnings per share (EPS) for the quarter. The company had revenue of $4.71 million for the quarter. ALT5 Sigma had a negative net margin of 2,483.94% and a negative return on equity of 68.25%.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.